Categories: News

How grass from China is changing lives in Fiji

GUANGZHOU, China, Oct. 16, 2025 /PRNewswire/ — News report from GDToday:

- Advertisement -

In Fiji, growing mushrooms was once considered impossible. However, a technology from China called Juncao, literally “mushroom grass,” has made it feasible, providing Fijian farmers with a sustainable method to cultivate edible fungi without the need to cut down trees.

- Advertisement -

At the China-Pacific Island Countries Juncao Technology Demonstration Center, local farmers are learning this technique from the ground up. So far, the center has conducted 65 training sessions, training over 2,800 technicians, and is expanding its programs to other Pacific nations.

- Advertisement -

For many farmers, Juncao cultivation means a steady income and new opportunities—sometimes earning up to 2,000 Fijian dollars a month.

- Advertisement -

In addition to improving livelihoods, Juncao is also aiding in the fight against soil erosion and in the restoration of degraded land.

- Advertisement -

In this episode, South journalist Liu Xiaodi visits the China-Pacific Island Countries Juncao Technology Demonstration Center in Fiji to explore how this “grass from China” is transforming local lives.

- Advertisement -

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/how-grass-from-china-is-changing-lives-in-fiji-302586223.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

9 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

9 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

9 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

9 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

9 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

9 hours ago